News & Events
James R. Berenson, MD, Inc. Announces Rebranding and Changes Organization Name to Berenson Cancer Center
New name, logo, and business unit alignment introduced as part of an extensive rebranding initiative
ONCOtracker And The Binding Site Announce a Global Diagnostic License And Collaboration On Solubilized B-cell Maturation Antigen (sBCMA), A Novel Blood-based Biomarker
ONCOtracker Signs Licensing Agreement with Juno Therapeutics; Provides Update on Internal Development
Los Angeles, CA – December 4, 2017 — ONCOtracker, Inc., a private medical diagnostics company, announced a license agreement with Juno Therapeutics (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, to advance its program in multiple myeloma using gamma secretase inhibitors (GSIs) in combination with BCMA-directed CAR T cells.
WEST HOLLYWOOD, Calif., March 12, 2019 /PRNewswire/ — ONCOtracker, Inc. announced that it has strengthened its intellectual property portfolio in multiple myeloma by completing an agreement with the Institute for Myeloma and Bone Cancer Research to acquire worldwide rights to its intellectual property regarding both diagnostic testing and a new therapeutic approach for treating these patients.
WEST HOLLYWOOD, Calif., Sept. 24, 2018 /PRNewswire/ — ONCOtracker, Inc. announced that its Chief Executive Officer, James Kuo, MD, MBA, has been invited to speak at the 20th Annual SoCalBio Conference taking place on Friday, September 28, 2018. Dr. Kuo will provide an update on ONCOtracker’s recent business activities and answer questions about the company. The conference will be held at the Westin Hotel in Long Beach, California. More information can be found at www.socalbio.org.